Anticancer efficacy and absorption, distribution, metabolism, and toxicity studies of aspergiolide A in early drug development

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1965-1977

  Wang, Yuanyuan ^a   Qi, Xin ^a   Li, Dehai ^a   Zhu, Tianjiao ^a   Mo, Xiaomei ^a   Li, Jing ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

ADMT; Anthracyclines; Anticancer; Aspergiolide A; Drug activity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ASPERGIOLIDE A; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; GYRASE INHIBITOR;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MICRONUCLEUS TEST; MOUSE; NONHUMAN; TISSUE DISTRIBUTION; TOXICITY TESTING; ABSORPTION; ANIMAL; CELL PROLIFERATION; CHEMICAL STRUCTURE; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; HELA CELL LINE; LIVER NEOPLASMS, EXPERIMENTAL; MCF 7 CELL LINE; METABOLISM; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ABSORPTION, PHYSIOLOGICAL; ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS; TUMOR CELLS, CULTURED;

EID: 84908285995     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S64989     Document Type: Article

References (23)

1. Liberra K, Lindequist U. Marine fungi – a prolific resource of biologically active natural products? Pharmazie. 1995;50(9): 583–588.
2. Belofsky GN, Jensen PR, Fenical W. Sansalvamide: a new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium. Tetrahedron Lett. 1999;40(15):2913–2916.
3. Du L, Zhu T, Fang Y, Liu H, Gu Q, Zhu W. Aspergiolide A, a novel anthraquinone derivative with naphtho[1,2,3-de]chromene-2,7-dione skeleton isolated from a marine-derived fungus Aspergillus glaucus. Tetrahedron. 2007;63(5):1085–1088.
4. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19(6):670–686.
5. Hodgson J. ADMET – turning chemicals into drugs. Nat Biotechnol. 2001;19(8):722–726.
6. Wang J. Comprehensive assessment of ADMET risks in drug discovery. Curr Pharm Des. 2009;15(19):2195–2219.
7. LeBeau JE. The role of the LD50 determination in drug safety evaluation. Regul Toxicol Pharmacol. 1983;3(1):71–74.
8. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature. 2009;458(7238):591–596.
9. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des. 1990;5(4): 307–317.
10. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463–469.
11. Vici P, Sergi D, Pizzuti L, et al. [Specificity of action of anticancer agents]. Clin Ter. 2011;162(2):137–149. Italian.
12. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res. 2008;14(16):1610–1617.
13. Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today. 2009;14(3–4):162–167.
14. Colbern GT, Hiller AJ, Musterer RS, Pegg E, Henderson IC, Working PK. Significant increase in anticancer potency of doxorubicin Hc1 by its encapsulation in pegylated liposomes. J Liposome Res. 1999;9(4):523–538.
15. Aleisa AM, Al-Rejaie SS, Bakheet SA, et al. Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice. Mutat Res. 2007;634(1–2):93–100.
16. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab. 2006;7(2):165–182.
17. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol. 2000;57(4):679–686.
18. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002;4(3):235–242.
19. Fagerholm U. Prediction of human pharmacokinetics – gastrointestinal absorption. J Pharm Pharmacol. 2007;59(7):905–916.
20. Ke W, Zhao Y, Huang R, Jiang C, Pei Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci. 2008;97(6):2208–2216.
21. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man – fact or myth. Pharm Res. 1997;14(6):763–766.
22. Mahar Doan KM, Humphreys JE, Webster LO, et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002;303(3):1029–1037.
23. Zunino F, Pratesi G, Perego P. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol. 2001;61(8):933–938.